GWPH

$214.85
-$0.15 (-0.1%)
Closing price February 25, 2021
London-based Jazz Pharmaceuticals has agreed to pay $7.2 billion to acquire GW Pharmaceuticals, a maker of drugs derived from cannabis plants.
As earnings season begins, Lululemon Athletica and other companies are updating guidance for the quarter just ended and for the 2020 fiscal year.
These four off-the-radar companies are executing well, and their shares look to have very solid upside to the latest Goldman Sachs price targets.
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
GW Pharmaceuticals shares popped early on Monday morning after the company announced that it received a key approval from the FDA for Epidiolex to treat certain seizures.
GW Pharmaceuticals took a big step forward for the development of its cannabidiol product in the United Kingdom.